Larimar Therapeutics, Inc.
LRMR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $237 | $200 | $106 | $185 |
| - Cash | $33 | $27 | $27 | $70 |
| + Debt | $5 | $6 | $5 | $6 |
| Enterprise Value | $209 | $179 | $85 | $121 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$91 | -$41 | -$36 | -$50 |
| % Margin | – | – | – | – |
| Net Income | -$81 | -$37 | -$35 | -$51 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.32 | -0.84 | -1.33 | -2.93 |
| % Growth | -57.1% | 36.8% | 54.6% | – |
| Operating Cash Flow | -$71 | -$33 | -$28 | -$42 |
| Capital Expenditures | -$1 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$71 | -$34 | -$28 | -$42 |